Analgesics..
Acetaminophen
Aspirin
Ibuprofen
Indomethacin
Antiandrogens..
All
Proxalutamide
Spironolactone
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Diet
Exercise
Sleep
Sun
Melatonin
Metformin
Molnupiravir
Monoclonals..
Bamlanivimab/etesevimab
Bebtelovimab
Casirivimab/imdevimab
Sotrovimab
Tixagevimab/cilgavimab
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Vitamin A
Vitamin C
Vitamin D
Zinc
Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes
Feedback
44 remdesivir COVID-19 controlled studies, 9 RCTs
15% improvement, RR 0.85 [0.77-0.94]
c19
early.org/s Jan 2023
Home
COVID-19 treatment studies for Remdesivir
COVID-19 treatment studies for Remdesivir
C19 studies: Remdesivir
Remdesivir
Select treatment
Select treatment
Treatments
Treatments
Analgesics..
Acetaminophen
Meta
Aspirin
Meta
Ibuprofen
Meta
Indomethacin
Meta
Close
Lifestyle..
Diet
Meta
Exercise
Meta
Sleep
Meta
Sun
Meta
Close
Antiandrogens..
All
Meta
Proxalutamide
Meta
Spironolactone
Meta
Close
Melatonin
Meta
Bromhexine
Meta
Metformin
Meta
Budesonide
Meta
Molnupiravir
Meta
Cannabidiol
Meta
Monoclonals..
Bamlaniv../e..
Meta
Bebtelovimab
Meta
Casirivimab/i..
Meta
Sotrovimab
Meta
Tixagev../c..
Meta
Close
Colchicine
Meta
Nigella Sativa
Meta
Conv. Plasma
Meta
Nitazoxanide
Meta
Curcumin
Meta
Nitric Oxide
Meta
Ensovibep
Meta
Paxlovid
Meta
Famotidine
Meta
Peg.. Lambda
Meta
Favipiravir
Meta
Povidone-Iod..
Meta
Fluvoxamine
Meta
Quercetin
Meta
Hydroxychlor..
Meta
Remdesivir
Meta
Iota-carragee..
Meta
Vitamins..
Vitamin A
Meta
Vitamin C
Meta
Vitamin D
Meta
Close
Ivermectin
Meta
Zinc
Meta
Lactoferrin
Meta
Other Treatments
Global Adoption
Outcomes in COVID-19 remdesivir studies
Home
Share
Tweet
Studies
Studies
Global Adoption
Adoption
Submit Feedback
Feedback
Analgesics..
Acetaminophen
Aspirin
Ibuprofen
Indomethacin
Antiandrogens..
All
Proxalutamide
Spironolactone
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Diet
Exercise
Sleep
Sun
Melatonin
Metformin
Molnupiravir
Monoclonals..
Bamlanivimab/etesevimab
Bebtelovimab
Casirivimab/imdevimab
Sotrovimab
Tixagevimab/cilgavimab
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Vitamin A
Vitamin C
Vitamin D
Zinc
Outcomes in remdesivir studies. Studies show significantly increased risk of acute kidney injury
[
Gérard
,
Zhou
]
.
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes
0
0.5
1
1.5+
All studies
15%
44
133,239
Improvement, Studies, Patients
Relative Risk
Mortality
16%
40
131,840
Ventilation
-10%
8
33,882
ICU admission
-34%
2
2,163
Hospitalization
-19%
4
3,939
Progression
47%
2
12,659
Recovery
21%
3
2,469
Viral clearance
0%
1
142
RCTs
12%
9
10,168
RCT mortality
9%
8
9,606
Peer-reviewed
9%
36
122,239
Early
61%
4
1,324
Late
14%
41
132,287
Remdesivir for COVID-19
c19
early.org/s Jan 2023
Favors
remdesivir
Favors
control
after exclusions
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Madan (ES)
66%
0.34 [0.12-0.96]
death
4/112
27/260
Improvement, RR [CI]
Treatment
Control
Gottlieb (DB RCT)
87%
0.13 [0.03-0.59]
death/hosp.
2/279
15/283
Piccicacco
66%
0.34 [0.01-8.32]
death
0/82
1/90
Kneidinger
20%
0.80 [0.35-1.82]
severe case
6/46
28/172
Tau
2
= 0.27, I
2
= 39.4%, p = 0.026
Early treatment
61%
0.39 [0.17-0.89]
12/519
71/805
61% improvement
Wang (RCT)
-9%
1.09 [0.54-2.18]
death
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Olender
59%
0.41 [0.24-0.71]
death
24/312
102/818
Spinner (RCT)
35%
0.65 [0.18-2.40]
death
5/384
4/200
Pasquini (ICU)
16%
0.84 [0.69-0.94]
death
14/25
24/26
ICU patients
Fried
61%
0.39 [0.15-0.99]
death
4/48
2,510/11,673
Beigel (RCT)
27%
0.73 [0.52-1.03]
death
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
death
301/2,743
303/2,708
Solh
47%
0.53 [0.39-0.70]
death
63/219
202/424
Flisiak
49%
0.51 [0.19-1.30]
death
5/122
17/211
Garibaldi
20%
0.80 [0.46-1.41]
death
23/303
45/303
Ullah
-100%
2.00 [0.67-5.94]
death
8/30
4/30
Yeramaneni
-24%
1.24 [0.11-14.2]
death
32 (n)
7,126 (n)
Goldberg
9%
0.91 [0.50-1.67]
hosp. time
29 (n)
113 (n)
Tsuzuki
-4%
1.04 [0.98-1.09]
death
69/824
285/11,663
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
death
5/34
3/36
Mulhem
-86%
1.86 [0.21-5.24]
death
1/8
515/3,211
Aghajani
19%
0.81 [0.46-1.46]
death
46 (n)
945 (n)
Elhadi (ICU)
-11%
1.11 [0.81-1.51]
death
14/21
267/444
ICU patients
Pourhoseingholi
-2%
1.02 [0.72-1.44]
death
42/123
297/2,345
Arch (PSM)
20%
0.80 [0.64-0.98]
death
203/1,491
777/4,676
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
death
3/37
4/53
Ohl (PSM)
-6%
1.06 [0.83-1.36]
death
143/1,172
124/1,172
Madan
44%
0.56 [0.33-0.95]
death
23/398
27/260
Kuno (PSM)
1%
0.99 [0.84-1.17]
death
214/999
216/999
Diaz
35%
0.65 [0.46-0.92]
death
33/286
173/852
DISCOVERY
Ader (RCT)
6%
0.94 [0.59-1.45]
death
34/414
37/418
Mozaffari
12%
0.88 [0.81-0.96]
death
4,441/28,855
5,499/28,855
Schmidt (PSM)
-509%
6.09 [2.71-13.7]
severe case
43 (n)
434 (n)
Jamir (ICU)
8%
0.92 [0.55-1.55]
death
60/181
41/85
ICU patients
Mustafa
33%
0.67 [0.38-1.20]
death
16/200
29/244
CATCO
Ali (RCT)
12%
0.88 [0.72-1.07]
death
127/634
152/647
Kurniyanto
-460%
5.60 [2.32-13.5]
death
7/45
12/432
Siraj
53%
0.47 [0.35-0.62]
death
108/413
197/587
Salehi (ICU)
37%
0.63 [0.43-0.94]
death
17/40
57/85
ICU patients
Elec
19%
0.81 [0.38-1.69]
death
7/38
29/127
Zangeneh (ICU)
32%
0.68 [0.45-1.01]
death
n/a
n/a
ICU patients
Malundo
-17%
1.17 [0.80-1.70]
death
24/115
197/1,100
Bowen
-57%
1.57 [1.25-1.97]
death
817 (n)
3,814 (n)
Raad
42%
0.58 [0.39-0.88]
death
n/a
n/a
Oku
-40%
1.40 [0.41-4.36]
death
3/46
8/172
Behboodikhah
38%
0.62 [0.30-1.30]
death
1,214 (n)
960 (n)
Tau
2
= 0.06, I
2
= 76.9%, p = 0.0042
Late treatment
14%
0.86 [0.78-0.95]
6,063/43,440
12,167/88,847
14% improvement
All studies
15%
0.85 [0.77-0.94]
6,075/43,959
12,238/89,652
15% improvement
Remdesivir COVID-19 studies
c19
early.org/s Jan 2023
Tau
2
= 0.06, I
2
= 76.1%, p = 0.0023
Effect extraction pre-specified
(most serious outcome)
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Gottlieb (DB RCT)
87%
0.13 [0.03-0.59]
death/hosp.
2/279
15/283
Improvement, RR [CI]
Treatment
Control
Piccicacco
66%
0.34 [0.01-8.32]
death
0/82
1/90
Kneidinger
20%
0.80 [0.35-1.82]
severe case
6/46
28/172
Tau
2
= 0.77, I
2
= 56.2%, p = 0.15
Early treatment
63%
0.37 [0.10-1.44]
8/407
44/545
63% improvement
Wang (RCT)
-9%
1.09 [0.54-2.18]
death
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Olender
59%
0.41 [0.24-0.71]
death
24/312
102/818
Spinner (RCT)
35%
0.65 [0.18-2.40]
death
5/384
4/200
Pasquini (ICU)
16%
0.84 [0.69-0.94]
death
14/25
24/26
ICU patients
Beigel (RCT)
27%
0.73 [0.52-1.03]
death
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
death
301/2,743
303/2,708
Flisiak
49%
0.51 [0.19-1.30]
death
5/122
17/211
Garibaldi
20%
0.80 [0.46-1.41]
death
23/303
45/303
Ullah
-100%
2.00 [0.67-5.94]
death
8/30
4/30
Yeramaneni
-24%
1.24 [0.11-14.2]
death
32 (n)
7,126 (n)
Goldberg
9%
0.91 [0.50-1.67]
hosp. time
29 (n)
113 (n)
Tsuzuki
-4%
1.04 [0.98-1.09]
death
69/824
285/11,663
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
death
5/34
3/36
Aghajani
19%
0.81 [0.46-1.46]
death
46 (n)
945 (n)
Pourhoseingholi
-2%
1.02 [0.72-1.44]
death
42/123
297/2,345
Arch (PSM)
20%
0.80 [0.64-0.98]
death
203/1,491
777/4,676
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
death
3/37
4/53
Ohl (PSM)
-6%
1.06 [0.83-1.36]
death
143/1,172
124/1,172
Kuno (PSM)
1%
0.99 [0.84-1.17]
death
214/999
216/999
Diaz
35%
0.65 [0.46-0.92]
death
33/286
173/852
DISCOVERY
Ader (RCT)
6%
0.94 [0.59-1.45]
death
34/414
37/418
Mozaffari
12%
0.88 [0.81-0.96]
death
4,441/28,855
5,499/28,855
Jamir (ICU)
8%
0.92 [0.55-1.55]
death
60/181
41/85
ICU patients
CATCO
Ali (RCT)
12%
0.88 [0.72-1.07]
death
127/634
152/647
Siraj
53%
0.47 [0.35-0.62]
death
108/413
197/587
Zangeneh (ICU)
32%
0.68 [0.45-1.01]
death
n/a
n/a
ICU patients
Bowen
-57%
1.57 [1.25-1.97]
death
817 (n)
3,814 (n)
Raad
42%
0.58 [0.39-0.88]
death
n/a
n/a
Behboodikhah
38%
0.62 [0.30-1.30]
death
1,214 (n)
960 (n)
Tau
2
= 0.04, I
2
= 72.4%, p = 0.0012
Late treatment
15%
0.85 [0.77-0.94]
5,884/42,219
8,314/70,241
15% improvement
All studies
16%
0.84 [0.76-0.93]
5,892/42,626
8,358/70,786
16% improvement
Remdesivir COVID-19 studies after exclusions
c19
early.org/s Jan 2023
Tau
2
= 0.04, I
2
= 71.3%, p = 0.00063
Effect extraction pre-specified
(most serious outcome)
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Madan (ES)
66%
0.34 [0.12-0.96]
4/112
27/260
Improvement, RR [CI]
Treatment
Control
Piccicacco
66%
0.34 [0.01-8.32]
0/82
1/90
Tau
2
= 0.00, I
2
= 0.0%, p = 0.032
Early treatment
66%
0.34 [0.13-0.91]
4/194
28/350
66% improvement
Wang (RCT)
-9%
1.09 [0.54-2.18]
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Olender
59%
0.41 [0.24-0.71]
24/312
102/818
Spinner (RCT)
35%
0.65 [0.18-2.40]
5/384
4/200
Pasquini (ICU)
16%
0.84 [0.69-0.94]
14/25
24/26
ICU patients
Fried
61%
0.39 [0.15-0.99]
4/48
2,510/11,673
Beigel (RCT)
27%
0.73 [0.52-1.03]
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
301/2,743
303/2,708
Solh
47%
0.53 [0.39-0.70]
63/219
202/424
Flisiak
49%
0.51 [0.19-1.30]
5/122
17/211
Garibaldi
20%
0.80 [0.46-1.41]
23/303
45/303
Ullah
-100%
2.00 [0.67-5.94]
8/30
4/30
Yeramaneni
-24%
1.24 [0.11-14.2]
32 (n)
7,126 (n)
Tsuzuki
-4%
1.04 [0.98-1.09]
69/824
285/11,663
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
5/34
3/36
Mulhem
-86%
1.86 [0.21-5.24]
1/8
515/3,211
Aghajani
19%
0.81 [0.46-1.46]
46 (n)
945 (n)
Elhadi (ICU)
-11%
1.11 [0.81-1.51]
14/21
267/444
ICU patients
Pourhoseingholi
-2%
1.02 [0.72-1.44]
42/123
297/2,345
Arch (PSM)
20%
0.80 [0.64-0.98]
203/1,491
777/4,676
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
3/37
4/53
Ohl (PSM)
-6%
1.06 [0.83-1.36]
143/1,172
124/1,172
Madan
44%
0.56 [0.33-0.95]
23/398
27/260
Kuno (PSM)
1%
0.99 [0.84-1.17]
214/999
216/999
Diaz
35%
0.65 [0.46-0.92]
33/286
173/852
DISCOVERY
Ader (RCT)
6%
0.94 [0.59-1.45]
34/414
37/418
Mozaffari
12%
0.88 [0.81-0.96]
4,441/28,855
5,499/28,855
Jamir (ICU)
8%
0.92 [0.55-1.55]
60/181
41/85
ICU patients
Mustafa
33%
0.67 [0.38-1.20]
16/200
29/244
CATCO
Ali (RCT)
12%
0.88 [0.72-1.07]
127/634
152/647
Kurniyanto
-460%
5.60 [2.32-13.5]
7/45
12/432
Siraj
53%
0.47 [0.35-0.62]
108/413
197/587
Salehi (ICU)
37%
0.63 [0.43-0.94]
17/40
57/85
ICU patients
Elec
19%
0.81 [0.38-1.69]
7/38
29/127
Zangeneh (ICU)
32%
0.68 [0.45-1.01]
n/a
n/a
ICU patients
Malundo
-17%
1.17 [0.80-1.70]
24/115
197/1,100
Bowen
-57%
1.57 [1.25-1.97]
817 (n)
3,814 (n)
Raad
42%
0.58 [0.39-0.88]
n/a
n/a
Oku
-40%
1.40 [0.41-4.36]
3/46
8/172
Behboodikhah
38%
0.62 [0.30-1.30]
1,214 (n)
960 (n)
Tau
2
= 0.05, I
2
= 74.8%, p = 0.00055
Late treatment
16%
0.84 [0.76-0.93]
6,063/43,368
12,167/88,300
16% improvement
All studies
16%
0.84 [0.76-0.93]
6,067/43,562
12,195/88,650
16% improvement
41 remdesivir COVID-19 mortality results
c19
early.org/s Jan 2023
Tau
2
= 0.05, I
2
= 74.2%, p = 0.0005
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fried
-37%
1.37 [0.81-2.30]
11/48
1,956/11,673
Improvement, RR [CI]
Treatment
Control
Ullah
-250%
3.50 [0.79-15.5]
7/30
2/30
Tsuzuki
2%
0.98 [0.91-1.07]
48/824
98/11,663
Mahajan (RCT)
-112%
2.12 [0.41-10.8]
4/34
2/36
Arch (PSM)
-68%
1.68 [1.19-2.34]
106/1,498
153/4,602
Kuno (PSM)
0%
1.00 [0.80-1.24]
140/999
140/999
CATCO
Ali (RCT)
47%
0.53 [0.38-0.75]
46/634
89/647
Elec
11%
0.89 [0.45-1.78]
8/38
30/127
Tau
2
= 0.15, I
2
= 79.9%, p = 0.6
Late treatment
-10%
1.10 [0.78-1.54]
370/4,105
2,470/29,777
-10% improvement
All studies
-10%
1.10 [0.78-1.54]
370/4,105
2,470/29,777
-10% improvement
8 remdesivir COVID-19 mechanical ventilation results
c19
early.org/s Jan 2023
Tau
2
= 0.15, I
2
= 79.9%, p = 0.6
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Kuno (PSM)
-17%
1.17 [1.00-1.37]
260/999
222/999
Improvement, RR [CI]
Treatment
Control
Elec
-72%
1.72 [1.11-2.66]
18/38
35/127
Tau
2
= 0.05, I
2
= 61.8%, p = 0.11
Late treatment
-34%
1.34 [0.94-1.92]
278/1,037
257/1,126
-34% improvement
All studies
-34%
1.34 [0.94-1.92]
278/1,037
257/1,126
-34% improvement
2 remdesivir COVID-19 ICU results
c19
early.org/s Jan 2023
Tau
2
= 0.05, I
2
= 61.8%, p = 0.11
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Piccicacco
30%
0.70 [0.28-1.72]
hosp.
7/82
11/90
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.44
Early treatment
30%
0.70 [0.28-1.72]
7/82
11/90
30% improvement
Goldberg
9%
0.91 [0.50-1.67]
hosp. time
29 (n)
113 (n)
Improvement, RR [CI]
Treatment
Control
Ohl (PSM)
-100%
2.00 [1.33-3.02]
hosp. time
1,172 (n)
1,172 (n)
CATCO
Ali (RCT)
-11%
1.11 [1.01-1.23]
hosp. time
634 (n)
647 (n)
Tau
2
= 0.10, I
2
= 74.9%, p = 0.25
Late treatment
-28%
1.28 [0.85-1.93]
0/1,835
0/1,932
-28% improvement
All studies
-19%
1.19 [0.82-1.72]
7/1,917
11/2,022
-19% improvement
4 remdesivir COVID-19 hospitalization results
c19
early.org/s Jan 2023
Tau
2
= 0.09, I
2
= 67.1%, p = 0.37
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Madan (ES)
66%
0.34 [0.12-0.96]
death
4/112
27/260
Improvement, RR [CI]
Treatment
Control
Gottlieb (DB RCT)
87%
0.13 [0.03-0.59]
death/hosp.
2/279
15/283
Piccicacco
66%
0.34 [0.01-8.32]
death
0/82
1/90
Kneidinger
20%
0.80 [0.35-1.82]
severe case
6/46
28/172
Tau
2
= 0.27, I
2
= 39.4%, p = 0.026
Early treatment
61%
0.39 [0.17-0.89]
12/519
71/805
61% improvement
Wang (RCT)
-9%
1.09 [0.54-2.18]
death
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Olender
59%
0.41 [0.24-0.71]
death
24/312
102/818
Spinner (RCT)
35%
0.65 [0.18-2.40]
death
5/384
4/200
Pasquini (ICU)
16%
0.84 [0.69-0.94]
death
14/25
24/26
ICU patients
Fried
61%
0.39 [0.15-0.99]
death
4/48
2,510/11,673
Beigel (RCT)
27%
0.73 [0.52-1.03]
death
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
death
301/2,743
303/2,708
Solh
47%
0.53 [0.39-0.70]
death
63/219
202/424
Flisiak
49%
0.51 [0.19-1.30]
death
5/122
17/211
Garibaldi
20%
0.80 [0.46-1.41]
death
23/303
45/303
Ullah
-100%
2.00 [0.67-5.94]
death
8/30
4/30
Yeramaneni
-24%
1.24 [0.11-14.2]
death
32 (n)
7,126 (n)
Tsuzuki
-4%
1.04 [0.98-1.09]
death
69/824
285/11,663
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
death
5/34
3/36
Mulhem
-86%
1.86 [0.21-5.24]
death
1/8
515/3,211
Aghajani
19%
0.81 [0.46-1.46]
death
46 (n)
945 (n)
Elhadi (ICU)
-11%
1.11 [0.81-1.51]
death
14/21
267/444
ICU patients
Pourhoseingholi
-2%
1.02 [0.72-1.44]
death
42/123
297/2,345
Arch (PSM)
20%
0.80 [0.64-0.98]
death
203/1,491
777/4,676
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
death
3/37
4/53
Ohl (PSM)
-6%
1.06 [0.83-1.36]
death
143/1,172
124/1,172
Madan
44%
0.56 [0.33-0.95]
death
23/398
27/260
Kuno (PSM)
1%
0.99 [0.84-1.17]
death
214/999
216/999
Diaz
35%
0.65 [0.46-0.92]
death
33/286
173/852
DISCOVERY
Ader (RCT)
6%
0.94 [0.59-1.45]
death
34/414
37/418
Mozaffari
12%
0.88 [0.81-0.96]
death
4,441/28,855
5,499/28,855
Schmidt (PSM)
-509%
6.09 [2.71-13.7]
severe case
43 (n)
434 (n)
Jamir (ICU)
8%
0.92 [0.55-1.55]
death
60/181
41/85
ICU patients
Mustafa
33%
0.67 [0.38-1.20]
death
16/200
29/244
CATCO
Ali (RCT)
12%
0.88 [0.72-1.07]
death
127/634
152/647
Kurniyanto
-460%
5.60 [2.32-13.5]
death
7/45
12/432
Siraj
53%
0.47 [0.35-0.62]
death
108/413
197/587
Salehi (ICU)
37%
0.63 [0.43-0.94]
death
17/40
57/85
ICU patients
Elec
19%
0.81 [0.38-1.69]
death
7/38
29/127
Zangeneh (ICU)
32%
0.68 [0.45-1.01]
death
n/a
n/a
ICU patients
Malundo
-17%
1.17 [0.80-1.70]
death
24/115
197/1,100
Bowen
-57%
1.57 [1.25-1.97]
death
817 (n)
3,814 (n)
Raad
42%
0.58 [0.39-0.88]
death
n/a
n/a
Oku
-40%
1.40 [0.41-4.36]
death
3/46
8/172
Behboodikhah
38%
0.62 [0.30-1.30]
death
1,214 (n)
960 (n)
Tau
2
= 0.06, I
2
= 77.5%, p = 0.0045
Late treatment
14%
0.86 [0.78-0.95]
6,063/43,411
12,167/88,734
14% improvement
All studies
15%
0.85 [0.77-0.94]
6,075/43,930
12,238/89,539
15% improvement
44 remdesivir COVID-19 serious outcomes
c19
early.org/s Jan 2023
Tau
2
= 0.06, I
2
= 76.7%, p = 0.0024
Effect extraction pre-specified
(most serious outcome)
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Gottlieb (DB RCT)
29%
0.71 [0.37-1.37]
no recov.
43/66
45/60
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.0033
Early treatment
29%
0.71 [0.37-1.37]
43/66
45/60
29% improvement
Beigel (RCT)
22%
0.78 [0.67-0.89]
no recov.
541 (n)
521 (n)
Improvement, RR [CI]
Treatment
Control
CATCO
Ali (RCT)
9%
0.91 [0.73-1.14]
no recov.
634 (n)
647 (n)
Tau
2
= 0.00, I
2
= 29.1%, p = 0.0096
Late treatment
18%
0.82 [0.71-0.95]
0/1,175
0/1,168
18% improvement
All studies
21%
0.79 [0.70-0.89]
43/1,241
45/1,228
21% improvement
3 remdesivir COVID-19 recovery results
c19
early.org/s Jan 2023
Tau
2
= 0.00, I
2
= 18.9%, p = 0.00016
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Goldberg
0%
1.00 [0.92-1.09]
viral+
29 (n)
113 (n)
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.98
Late treatment
0%
1.00 [0.92-1.09]
0/29
0/113
0% improvement
All studies
0%
1.00 [0.92-1.09]
0/29
0/113
0% improvement
1 remdesivir COVID-19 viral clearance result
c19
early.org/s Jan 2023
Tau
2
= 0.00, I
2
= 0.0%, p = 0.98
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Gottlieb (DB RCT)
87%
0.13 [0.03-0.59]
death/hosp.
2/279
15/283
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.0064
Early treatment
87%
0.13 [0.03-0.59]
2/279
15/283
87% improvement
Wang (RCT)
-9%
1.09 [0.54-2.18]
death
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Spinner (RCT)
35%
0.65 [0.18-2.40]
death
5/384
4/200
Beigel (RCT)
27%
0.73 [0.52-1.03]
death
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
death
301/2,743
303/2,708
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
death
5/34
3/36
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
death
3/37
4/53
DISCOVERY
Ader (RCT)
6%
0.94 [0.59-1.45]
death
34/414
37/418
CATCO
Ali (RCT)
12%
0.88 [0.72-1.07]
death
127/634
152/647
Tau
2
= 0.00, I
2
= 0.0%, p = 0.087
Late treatment
9%
0.91 [0.82-1.01]
497/4,945
513/4,661
9% improvement
All studies
12%
0.88 [0.76-1.03]
499/5,224
528/4,944
12% improvement
9 remdesivir COVID-19 Randomized Controlled Trials
c19
early.org/s Jan 2023
Tau
2
= 0.01, I
2
= 21.5%, p = 0.11
Effect extraction pre-specified
(most serious outcome)
Favors remdesivir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Wang (RCT)
-9%
1.09 [0.54-2.18]
22/158
10/78
Improvement, RR [CI]
Treatment
Control
Spinner (RCT)
35%
0.65 [0.18-2.40]
5/384
4/200
Beigel (RCT)
27%
0.73 [0.52-1.03]
541 (n)
521 (n)
SOLIDARITY (RCT)
5%
0.95 [0.81-1.11]
301/2,743
303/2,708
Mahajan (RCT)
-76%
1.76 [0.46-6.82]
5/34
3/36
Barrat-Due (DB RCT)
0%
1.00 [0.20-4.60]
3/37
4/53
DISCOVERY
Ader (RCT)
6%
0.94 [0.59-1.45]
34/414
37/418
CATCO
Ali (RCT)
12%
0.88 [0.72-1.07]
127/634
152/647
Tau
2
= 0.00, I
2
= 0.0%, p = 0.087
Late treatment
9%
0.91 [0.82-1.01]
497/4,945
513/4,661